1. Home
  2. MDXH vs TLSA Comparison

MDXH vs TLSA Comparison

Compare MDXH & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.46

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.48

Market Cap

182.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDXH
TLSA
Founded
2003
2013
Country
Belgium
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
182.7M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
MDXH
TLSA
Price
$3.46
$1.48
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$7.67
N/A
AVG Volume (30 Days)
125.1K
450.6K
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$103,069,000.00
N/A
Revenue This Year
$23.34
N/A
Revenue Next Year
$22.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.68
N/A
52 Week Low
$1.35
$0.63
52 Week High
$5.33
$2.60

Technical Indicators

Market Signals
Indicator
MDXH
TLSA
Relative Strength Index (RSI) 45.66 38.06
Support Level $3.11 $1.36
Resistance Level $3.40 $1.62
Average True Range (ATR) 0.17 0.17
MACD 0.02 -0.02
Stochastic Oscillator 50.00 34.62

Price Performance

Historical Comparison
MDXH
TLSA

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: